A laboratory study of hydromorphone and cyclazocine on smoking behavior in residential polydrug users

Wallace B. Pickworth, Eun M. Lee, Mary E. Abreu, Annie Umbricht, Kenzie L. Preston

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


The effects of cyclazocine and hydromorphone on spontaneous and laboratory cigarette smoking were compared in a double-blind, placebo-controlled, crossover study. Participants (seven men, one woman) received oral doses of placebo, cyclazocine (0.2, 0.4, and 0.8 mg) and hydromorphone (5 and 15 mg) in a randomized order on experimental days. Spontaneous smoking was recorded during two intervals on the experimental days: a 3-h period 5-8 h after drug administration (Interval 1), and the rest of the day (Interval 2). Measures of smoking topography and subjective and physiologic effects of a single cigarette were obtained on the experimental days. Neither hydromorphone nor cyclazocine significantly changed spontaneous smoking when compared to the placebo condition; however, compared to hydromorphone (5 mg), cyclazocine (0.4 and 0.8 mg) decreased spontaneous smoking during Interval 1. Hydromorphone (5 and 15 mg) and cyclazocine (0.4 and 0.8 mg) diminished smoking-induced increases in heart rate. Compared to the placebo condition, cyclazocine (0.2 and 0.4 mg) reduced exhaled carbon monoxide (CO) boost, a measure of smoke exposure. Further studies of the effects of kappa opioid agonists on smoking behavior may lead to a better understanding of the role of opiates in smoking behavior.

Original languageEnglish (US)
Pages (from-to)711-715
Number of pages5
JournalPharmacology Biochemistry and Behavior
Issue number4
StatePublished - Apr 2004
Externally publishedYes


  • Cyclazocine
  • Hydromorphone
  • Kappa opioid agonist
  • Polydrug use
  • Smoking

ASJC Scopus subject areas

  • Biochemistry
  • Toxicology
  • Pharmacology
  • Clinical Biochemistry
  • Biological Psychiatry
  • Behavioral Neuroscience


Dive into the research topics of 'A laboratory study of hydromorphone and cyclazocine on smoking behavior in residential polydrug users'. Together they form a unique fingerprint.

Cite this